SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-026563
Filing Date
2023-08-02
Accepted
2023-08-02 06:50:55
Documents
19
Period of Report
2023-08-02
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20230802.htm   iXBRL 8-K 28656
2 EX-99.1 pressrelease-2q23financi.htm EX-99.1 20228
6 pressrelease-2q23financi001.jpg GRAPHIC 230928
7 pressrelease-2q23financi002.jpg GRAPHIC 280654
8 pressrelease-2q23financi003.jpg GRAPHIC 241326
9 pressrelease-2q23financi004.jpg GRAPHIC 197986
10 pressrelease-2q23financi005.jpg GRAPHIC 222522
11 pressrelease-2q23financi006.jpg GRAPHIC 168987
  Complete submission text file 0001628280-23-026563.txt   2037601

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20230802.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20230802_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20230802_pre.xml EX-101.PRE 13060
13 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20230802_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 231133646
SIC: 2834 Pharmaceutical Preparations